• Dosage of Moxifloxacine VIOSER in details
• Moxifloxacine VIOSER interactions
• Moxifloxacine VIOSER reviews

Dosage of Moxifloxacine VIOSER in details

Moxifloxacine VIOSER Dosage

Generic name: Moxifloxacine VIOSER HYDROCHLORIDE 400mg in 250mL

Dosage form: tablet, film coated; injection, solution

See also:

• Moxifloxacine VIOSER ABC Pack tablet, injection
• Moxifloxacine VIOSER Injection injection, solution; tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Dosage in Adult Patients

The dose of Moxifloxacine VIOSER is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.

Table 1: Dosage and Duration of Therapy in Adult Patients

Type of Infectiona	Dose Every 24 hours	Durationb (days)
Community Acquired Pneumonia (1.1)	400 mg	7–14
Uncomplicated Skin and Skin Structure Infections (SSSI ) (1.2)	400 mg	7
Complicated SSSI (1.3)	400 mg	7–21
Complicated Intra-Abdominal Infections (1.4)	400 mg	5–14
Plague (1.5)C	400 mg	10–14
Acute Bacterial Sinusitis (ABS) (1.6)	400 mg	10
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) (1.7)	400 mg	5

a)

Due to the designated pathogens.

b)

Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician

c)

Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.

Conversion of

Intravenous to

Oral Dosing in Adults

Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with Moxifloxacine VIOSER Injection may be switched to Moxifloxacine VIOSER Tablets when clinically indicated at the discretion of the physician.

Important Administration Instructions

Moxifloxacine VIOSER Tablets

With Multivalent Cations

Administer Moxifloxacine VIOSER Tablets at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins and didanosine buffered tablets for oral suspension or the pediatric powder for oral solution.

With Food

Moxifloxacine VIOSER Tablets can be taken with or without food, drink fluids liberally.

Moxifloxacine VIOSER Injection

Administer by

Intravenous infusion only. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.

Administer by intravenous infusion over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place. Avoid rapid or bolus intravenous infusion.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Discard any unused portion because the premix flexible containers are for single-use only.

Drug and Diluent Compatibilities

Because only limited data are available on the compatibility of Moxifloxacine VIOSER intravenous injection with other intravenous substances, additives or other medications should not be added to Moxifloxacine VIOSER Injection or infused simultaneously through the same intravenous line. If the same intravenous line or a Y-type line is used for sequential infusion of other drugs, or if the “piggyback” method of administration is used, the line should be flushed before and after infusion of Moxifloxacine VIOSER Injection with an infusion solution compatible with Moxifloxacine VIOSER Injection as well as with other drug(s) administered via this common line.

Compatible

Intravenous Solutions: Moxifloxacine VIOSER Injection is compatible with the following intravenous solutions at ratios from 1:10 to 10:1:

0.9% Sodium Chloride Injection, USP

1 Molar Sodium Chloride Injection

5% Dextrose Injection, USP

Sterile Water for Injection, USP

10% Dextrose for Injection, USP

Lactated Ringer’s for Injection

Preparation for Administration of Moxifloxacine VIOSER Injection

Refer to complete directions that have been provided with the administration set.

To prepare Moxifloxacine VIOSER Injection premix in flexible containers:

Close flow control clamp of administration set.

Remove cover from port at bottom of container.

Insert piercing pin from an appropriate transfer set (for example, one that does not require excessive force, such as ISO compatible administration set) into port with a gentle twisting motion until pin is firmly seated.

More about Moxifloxacine VIOSER (Moxifloxacine VIOSER)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• Pricing & Coupons
• En Espanol
• 143 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Moxifloxacine VIOSER
• Moxifloxacine VIOSER tablets
• Moxifloxacine VIOSER (Advanced Reading)

Professional resources

• Moxifloxacine VIOSER (AHFS Monograph)
• More (2) »

Other formulations

• Moxifloxacine VIOSER I.V.

Related treatment guides

• Bacterial Infection
• Bronchitis
• Cutaneous Bacillus anthracis
• Intraabdominal Infection
• Plague
• More (6) »

What other drugs will affect Moxifloxacine VIOSER?

Some medicines can make Moxifloxacine VIOSER much less effective when taken at the same time. If you take any of the following medicines, take your Moxifloxacine VIOSER dose 4 hours before or 8 hours after you take the other medicine:

• the ulcer medicine sucralfate, or antacids that contain calcium, magnesium, or aluminum (such as Maalox, Milk of Magnesia, Mylanta, Pepcid Complete, Rolaids, Tums, and others);

• didanosine (Videx) powder or chewable tablets;

• lanthanum carbonate or sevelamer; or

• vitamin or mineral supplements that contain aluminum, iron, magnesium, or zinc.

Tell your doctor about all your other medicines, especially:

• erythromycin;

• a blood thinner (warfarin, Coumadin, Jantoven);

• a diuretic or "water pill";

• heart rhythm medication;

• insulin or oral diabetes medicine (check your blood sugar regularly);

• medicine to treat depression or mental illness;

• steroid medicine (such as prednisone); or

• NSAIDs (nonsteroidal anti-inflammatory drugs)--aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others.

This list is not complete. Other drugs may affect Moxifloxacine VIOSER, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

See also:

Moxifloxacine VIOSER drug interactions (in more detail)

Moxifloxacine VIOSER interactions

Tablet: For the following substances, absence of a clinically relevant interaction with Moxifloxacine VIOSER was proven: Atenolol, ranitidine, calcium supplements, theophylline, oral contraceptives, glibenclamide, itraconazole, digoxin, morphine, probenecid. No dose adjustment is necessary for these drugs.

Antacids, Minerals and Multivitamins: Concomitant ingestion of Moxifloxacine VIOSER with antacids, minerals and multivitamins may result in impaired absorption of Moxifloxacine VIOSER after oral administration due to formation of chelate complexes with the multivalent cations contained in these preparations. This may lead to plasma concentrations considerably lower than desired. Hence, antacids, antiretroviral drugs (eg, didanosine) and other preparations containing magnesium or aluminium, sucralfate and agents containing iron or zinc should be administered at least 4 hours before or 2 hours after ingestion of an oral Moxifloxacine VIOSER dose.

Ranitidine: The concomitant administration with ranitidine did not change the absorption characteristics of Moxifloxacine VIOSER. Absorption parameters (C_max, t_max, AUC) were comparable, indicating absence of an influence of gastric pH on Moxifloxacine VIOSER uptake from the gastrointestinal tract.

Calcium Supplements: When given with high dose calcium supplements, only a slightly reduced rate of absorption was observed, while extent of absorption remained unaffected. The effect of high-dose calcium supplements on the absorption of Moxifloxacine VIOSER is considered as clinically not relevant.

Theophylline: In accordance with in vitro data, no influence of Moxifloxacine VIOSER on theophylline pharmacokinetics (and vice versa) at steady state was detected in humans, indicating that Moxifloxacine VIOSER does not interfere with the 1A2 subtypes of the CYP450 enzymes.

Warfarin: No interaction during concomitant treatment with warfarin on pharmacokinetics, prothrombin time and other coagulation parameters has been observed.

Changes in International Normalized Ratio (INR): Cases of increased anticoagulant activity have been reported in patients receiving anticoagulants concurrently with antibiotics, including Moxifloxacine VIOSER. The infectious disease (and its accompanying inflammatory process), age and general status of the patient are risk factors. Although an interaction between Moxifloxacine VIOSER and warfarin was not demonstrated in clinical trials, INR monitoring should be performed and, if necessary, the oral anticoagulant dosage should be adjusted as appropriate.

Oral Contraceptives:

No interaction has occured following concomitant oral administration of Moxifloxacine VIOSER with oral contraceptives.

Antidiabetics: No clinically relevant interaction was seen between glibenclamide and Moxifloxacine VIOSER.

Itraconazole: Exposure (AUC) to itraconazole was only marginally altered under concomitant Moxifloxacine VIOSER treatment. Pharmacokinetics of Moxifloxacine VIOSER were not significantly altered by itraconazole. No dose adjustment is necessary for itraconazole when given with Moxifloxacine VIOSER and vice versa.

Digoxin: The pharmacokinetics of digoxin are not significantly influenced by Moxifloxacine VIOSER (and vice versa). After repeated dosing in healthy volunteers, Moxifloxacine VIOSER increased C_max of digoxin by approximately 30% at steady state without affecting AUC or trough levels.

Morphine:

Parenteral administration of morphine with Moxifloxacine VIOSER did not reduce the oral bioavailability of Moxifloxacine VIOSER and only slighlty decreased C_max (17 %).

Atenolol: The pharmacokinetics of atenolol are not significantly altered by Moxifloxacine VIOSER. Following single dose administration in healthy subjects, AUC was marginally increased (by approximately 4%) and peak concentrations were decreased by 10%.

Probenecid: No significant effect on apparent total body clearance and renal clearance of Moxifloxacine VIOSER was found in a clinical study investigating the impact of probenecid on renal excretion.

Charcoal: Concomitant dosing of charcoal and oral Moxifloxacine VIOSER 400 mg reduced the systemic availability of the drug by >80% by preventing absorption in vivo. The application of activated charcoal in the early absorption phase prevents further increase of systemic exposure in cases of overdose.

After IV drug administration, carbo medicinalis only slightly reduces systemic exposure (approximately 20%).

Food and Dairy Products: Absorption of Moxifloxacine VIOSER was not altered by food intake (including dairy products). Moxifloxacine VIOSER can be taken independent from food intake.

Infusion: No interaction during concomitant treatment with warfarin, itraconazole, theophylline, digoxin and oral contraceptives.

References

1. FDA/SPL Indexing Data. "U188XYD42P: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
2. MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
3. European Chemicals Agency - ECHA. "1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Moxifloxacine VIOSER are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Moxifloxacine VIOSER. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 25 here

Information checked by Dr. Sachin Kumar, MD Pharmacology